Sees Q1 adjusted EBITDA loss of $1M to gain of $1M. Sees Q1 billings $105M-$109M. “Achieving growth and improving our capital structure are our top priorities,” said Alexis DeSieno, CFO of Cardlytics. “In 2023, we turned to full year positive Adjusted EBITDA for the first time since 2019, and our Q1 guidance implies further acceleration. We are on a path to double-digit billings growth in 2024 and positive operating cash flow on an annual basis.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CDLX:
- Cardlytics Announces Fourth Quarter and Full Year 2023 Financial Results
- Cardlytics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Cardlytics Announces Timing of Its Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast
- Cardlytics, Inc. (CDLX) Q4 Earnings Cheat Sheet
- Cardlytics price target lowered to $10 from $12 at Craig-Hallum
